{"transactions":[{"id":949848,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T16:30:18.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":false,"shares":44250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."}],"balance_after":88500,"derivative":{"underlying":"Common Stock","underlying_shares":44250},"source":{"system":"sec-edgar","filing":"0001193125-26-002512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312526002512/ownership.xml","form_type":"4"}},{"id":949847,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T16:30:18.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":1500258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 3 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met."},{"field":"shares","element":"transactionShares","label":"F3","text":"The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":1500258,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":1500258},"source":{"system":"sec-edgar","filing":"0001193125-26-002512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312526002512/ownership.xml","form_type":"4"}},{"id":949846,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:18.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":44250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."}],"balance_after":325422,"source":{"system":"sec-edgar","filing":"0001193125-26-002512","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312526002512/ownership.xml","form_type":"4"}},{"id":988339,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":700000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988338,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":700000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988337,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":350000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988336,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.69,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988335,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":150000,"derivative":{"exercise_price":1.5,"expiration_date":"2031-02-21","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988334,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":12.66,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988333,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 22, 2021. The shares underlying the option began vesting on January 1, 2022 and continue to vest in equal monthly installments thereafter through December 1, 2025."}],"balance_after":100000,"derivative":{"exercise_price":1.5,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988332,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 22, 2021. The shares underlying the option began vesting on January 1, 2022 and continue to vest in equal monthly installments thereafter through December 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":13.83,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988331,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":50041,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":50041,"derivative":{"exercise_price":1.5,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":50041},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988330,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50041,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":50041},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988329,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":135134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":135134,"derivative":{"exercise_price":1.5,"expiration_date":"2031-08-22","underlying":"Common Stock","underlying_shares":135134},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988328,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.69,"expiration_date":"2031-08-22","underlying":"Common Stock","underlying_shares":135134},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988327,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":473334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":473334,"derivative":{"exercise_price":1.5,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":473334},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988326,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":473334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.89,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":473334},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988325,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":239703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":239703,"derivative":{"exercise_price":1.5,"expiration_date":"2030-07-22","underlying":"Common Stock","underlying_shares":239703},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988324,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":239703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.51,"expiration_date":"2030-07-22","underlying":"Common Stock","underlying_shares":239703},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":988323,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T16:10:03.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":2075000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 1 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":2075000,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":2075000},"source":{"system":"sec-edgar","filing":"0001193125-25-297203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000119312525297203/ownership.xml","form_type":"4"}},{"id":1105895,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-06-18T16:56:47.000Z","date":"2025-06-16","kind":"purchase","planned":false,"acquired":true,"shares":36289,"price":0.6801,"value":24680.1489,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6551 to $0.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":281172,"source":{"system":"sec-edgar","filing":"0001415889-25-017704","document":"form4-06182025_080644.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588925017704/form4-06182025_080644.xml","form_type":"4"}},{"id":1170800,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-16T16:30:17.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 15, 2025 and will vest in equal monthly installments beginning on May 1, 2025 through April 1, 2029."}],"balance_after":190000,"derivative":{"exercise_price":0.712,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001415889-25-010805","document":"form4-04162025_040405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588925010805/form4-04162025_040405.xml","form_type":"4"}},{"id":1313285,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T16:15:17.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":638000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029."}],"balance_after":638000,"derivative":{"exercise_price":0.955,"expiration_date":"2035-12-31","underlying":"Common Stock","underlying_shares":638000},"source":{"system":"sec-edgar","filing":"0001415889-25-000405","document":"form4-01032025_040111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588925000405/form4-01032025_040111.xml","form_type":"4"}},{"id":1313284,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T16:15:17.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":44250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs) convert to stock on a one-for-one basis"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."}],"balance_after":132750,"derivative":{"underlying":"Common Stock","underlying_shares":44250},"source":{"system":"sec-edgar","filing":"0001415889-25-000405","document":"form4-01032025_040111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588925000405/form4-01032025_040111.xml","form_type":"4"}},{"id":1313283,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-01-03T16:15:17.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":true,"shares":44250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs) convert to stock on a one-for-one basis"}],"balance_after":244883,"source":{"system":"sec-edgar","filing":"0001415889-25-000405","document":"form4-01032025_040111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588925000405/form4-01032025_040111.xml","form_type":"4"}},{"id":1527396,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-03T16:10:14.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":474000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028."}],"balance_after":474000,"derivative":{"exercise_price":1.08,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":474000},"source":{"system":"sec-edgar","filing":"0001415889-24-012149","document":"form4-05032024_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588924012149/form4-05032024_040501.xml","form_type":"4"}},{"id":1690678,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-01-03T16:15:18.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":177000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."}],"balance_after":177000,"derivative":{"underlying":"Common Stock","underlying_shares":177000},"source":{"system":"sec-edgar","filing":"0001415889-24-000276","document":"form4-01032024_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588924000276/form4-01032024_040101.xml","form_type":"4"}},{"id":1801499,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-18T20:45:25.000Z","date":"2023-08-16","kind":"grant","planned":false,"acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date."}],"balance_after":700000,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001415889-23-012418","document":"form4-08182023_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588923012418/form4-08182023_080801.xml","form_type":"4"}},{"id":2065437,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-04T16:14:08.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on January 1, 2023 and shall vest on February 1, 2023  with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until January 1, 2027."}],"balance_after":350000,"derivative":{"exercise_price":2.69,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001415889-23-000291","document":"form4-01042023_090151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588923000291/form4-01042023_090151.xml","form_type":"4"}},{"id":2373921,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-24T17:30:15.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026."}],"balance_after":150000,"derivative":{"exercise_price":12.66,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-22-001791","document":"form4-02242022_050201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588922001791/form4-02242022_050201.xml","form_type":"4"}},{"id":2447180,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-04T17:32:35.000Z","date":"2021-12-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on December 22, 2021 and shall vest on January 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until December 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the stock option shall continue to vest until December 1, 2026. This amendment is being filed solely to correct such date to December 1, 2025, as set forth in footnote 1."}],"balance_after":100000,"derivative":{"exercise_price":13.83,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-000247","document":"form4a-01042022_020119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588922000247/form4a-01042022_020119.xml","form_type":"4/A","original_submission_date":"2021-12-23"}},{"id":2459232,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND PRESIDENT"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-23T19:06:39.000Z","date":"2021-12-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on December 22, 2021 and shall vest on January 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until December 1, 2026."}],"balance_after":100000,"derivative":{"exercise_price":13.83,"expiration_date":"2031-12-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-21-006215","document":"form4-12232021_041229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000141588921006215/form4-12232021_041229.xml","form_type":"4"}},{"id":2535357,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2021-10-25T17:18:55.000Z","date":"2021-10-21","kind":"grant","acquired":true,"shares":50041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on October 21, 2021 and shall begin to vest on November 1, 2021 and continue to vest in equal monthly installments thereafter until October 1, 2025."}],"balance_after":50041,"derivative":{"exercise_price":16,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":50041},"source":{"system":"sec-edgar","filing":"0001104659-21-129572","document":"tm2130646-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000110465921129572/tm2130646-23_4seq1.xml","form_type":"4"}},{"id":2609707,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-09T19:55:19.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":35593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third (1/3) of the option shall vest on August 5, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 5th day of each month, subject to the Reporting Person's continuous service on each vesting date."}],"balance_after":35593,"derivative":{"exercise_price":17,"expiration_date":"2031-08-04","underlying":"Common Stock","underlying_shares":35593},"source":{"system":"sec-edgar","filing":"0001209191-21-050489","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722066/000120919121050489/doc4.xml","form_type":"4"}},{"id":2685948,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T20:57:51.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":6000,"price":9.5,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":6000,"derivative":{"exercise_price":9.5,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-21-011534","document":"wf-form4_162266743993002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021011534/wf-form4_162266743993002.xml","form_type":"4"}},{"id":3113017,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T12:31:41.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":3427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":3427,"derivative":{"exercise_price":8.69,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":3427},"source":{"system":"sec-edgar","filing":"0001628280-20-009238","document":"wf-form4_159187868380574.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828020009238/wf-form4_159187868380574.xml","form_type":"4"}},{"id":3483791,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-19T20:19:27.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":3427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8.3333% of the shares subject to the option shall vest on July 17, 2019, with the remainder vesting in equal monthly installments of 8.3333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant), subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":3427,"derivative":{"exercise_price":14.75,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":3427},"source":{"system":"sec-edgar","filing":"0000899243-19-017423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924319017423/doc4.xml","form_type":"4"}},{"id":4002810,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":70240,"kind":"person","name":"Russo Rene","position":1,"cik":"0001722066","reported_name":"Russo Rene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2018-03-09T21:35:07.000Z","date":"2018-03-07","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 25% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the fourth anniversary of the date of grant."}],"balance_after":160000,"derivative":{"exercise_price":17.34,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-18-018513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000120919118018513/doc4.xml","form_type":"4"}}]}